Partner Article

NGS technology Market Opportunities & Growth

Cancer Genetics, Inc. (CGI), an emerging market players in the field of personalized medicine, that offers diagnostic products & services in precision medicine for cancer treatment, earlier this month, has announced the commercial launch of its next generation sequencing (NGS) assay, following the successful CLIA validation for solid tumors. The product named FOCUS::ONCOMINE™ helps to understand molecular pathways with sound clinical evidence by making simultaneous testing of RNA and DNA. The assay in a single workflow enables sequencing of variety of genes.

The product FOCUS::ONCOMINE assay boasts of rapid turnaround time and is capable of detecting at least thousands biomarkers, that are clinically and pharmacologically relevant.

The next-generation sequencing (NGS) technology, as the company claims, is unique since it addresses a key constraining concern in solid tumor testing constrained by the scarcity of tissue material. This assay require minimal sample input per test and further enables accurate and reliable analysis of genomic sequences from different tumor sample types.

The assay is based on Thermo Fisher Scientific’s Oncomine Focus assay and includes 52 key genes having multiple alterations in solid tumors targeted by many oncology drugs currently in the market and several published evidence identified by leading organizations such as American Society of Clinical Oncology (ASCO), National Comprehensive Cancer Network (NCCN) and College of American Pathologists (CAP).

According to Panna Sharma, CEO & President of CGI. “For our biopharma customers, profiling with clinically actionable solid tumor panels can provide a view of pathway alterations, which links potential biomarkers to access clinical outcomes in prospective or retrospective studies at a cost similar to Sanger sequencing of just a few genes”.

A rigorous understanding of the genetic characteristics responsible for tumorigenesis using advanced technologies, like NGS, have led to the application of precision medicine to gain prominence in oncology. The NGS technology holds great potential in diagnostics and biotechnology industry, however their accuracy is limited by the factor that the tissue specimen shows a mixture of different cell types present in varied proportion.

Various researchers and clinical trials, conducted using advanced technology such as NGS, continue to expand understanding of healthcare providers and clinicians the tumor cells and help pharmaceutical manufacturers to make highly effective oncology drugs. Recently, Big Market Research has added a report title “Global Next Generation Sequencing Industry 2016 Deep Market Research Report”. The study highlights key industry developments in next-generation sequencing, recent technology innovations, key market dynamics, changing competitive landscape scenario along with profile of prominent market players across regions.

Source: http://www.bigmarketresearch.com/

This was posted in Bdaily's Members' News section by Stefania Lori .